Emalex clears Phase 3 for Tourette syndrome, will seek FDA approval

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a Phase 3 study, and now plans to take the drug to regulators for approval. The study ...